Oliván Martinez J, Garcia M J, Rodriguez Botaro A, Pizarro J L, Carretero J, Garrido M
Hypertension Unit of Macarena Hospital, Sevilla, Spain.
J Cardiovasc Pharmacol. 1990;16 Suppl 5:S95-9.
Forty outpatients (11 men and 29 women) aged between 65 and 85 years (mean age of 68 years) with mild to moderate hypertension [mean systolic/diastolic blood pressure (SBP/DBP) after 2 weeks on placebo of 175/102 mm Hg] were included in a randomized, double-blind, parallel-group study to compare the efficacy and tolerance of 10 mg of bisoprolol once daily (o.d., n = 20) and 20 mg of nifedipine sustained release (SR) b.i.d. (n = 20) during 4 weeks of treatment. SBP and DBP were significantly reduced compared to baseline with both treatments. There was no significant difference in efficacy between the two treatments after 2 and 4 weeks. After 2 weeks, the number of patients with normalized DBP (< or =90 mm Hg) was higher with bisoprolol than with nifedipine, this difference no longer being present after 4 weeks. Resting heart rate was significantly reduced with bisoprolol from 78+/-8 to 68+/-9 beats/min after 4 weeks, but there was no change in heart rate with nifedipine. Adverse events were reported by 6 patients on bisoprolol (20 events) and 12 patients on nifedipine (51 events) and the overall tolerance of bisoprolol was considered to be significantly better than that of nifedipine. Because bisoprolol is equally effective when administered once daily in comparison with nifedipine SR, which has to be given twice daily, and since bisoprolol exhibits a better tolerance, this beta-blocker appears to be a useful drug of first choice for the treatment of elderly hypertensive patients.
40名年龄在65至85岁(平均年龄68岁)的门诊患者(11名男性和29名女性),患有轻度至中度高血压[安慰剂治疗2周后的平均收缩压/舒张压(SBP/DBP)为175/102 mmHg],被纳入一项随机、双盲、平行组研究,以比较每日一次口服10 mg比索洛尔(n = 20)和每日两次口服20 mg硝苯地平缓释片(SR)(n = 20)在4周治疗期间的疗效和耐受性。与基线相比,两种治疗方法的SBP和DBP均显著降低。2周和4周后,两种治疗方法的疗效无显著差异。2周后,比索洛尔使DBP恢复正常(≤90 mmHg)的患者数量高于硝苯地平,4周后这种差异不再存在。4周后,比索洛尔使静息心率从78±8次/分钟显著降至68±9次/分钟,但硝苯地平对心率无影响。服用比索洛尔的6名患者(20起事件)和服用硝苯地平的12名患者(51起事件)报告了不良事件,比索洛尔的总体耐受性被认为明显优于硝苯地平。由于与每日需服用两次的硝苯地平缓释片相比,比索洛尔每日服用一次时疗效相同,且比索洛尔耐受性更好,因此这种β受体阻滞剂似乎是治疗老年高血压患者的一种有用的首选药物。